State Street Corp Avrobio, Inc. Transaction History

State Street Corp

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$0.75 - $1.33 $363,719 - $644,995	-484,959 Reduced 77.49%	140,852 $130,000
Q1 2022 May 16, 2022	SELL	$1.29 - $4.04 $274,371 - $859,271	-212,691 Reduced 25.37%	625,811 $826,000
Q4 2021 Feb 14, 2022	SELL	$3.45 - $6.05 $217,070 - $380,659	-62,919 Reduced 6.98%	838,502 $3.23 Million
Q3 2021 Nov 15, 2021	SELL	$5.53 - $9.28 $10.3 Million - $17.4 Million	-1,870,329 Reduced 67.48%	901,421 $5.03 Million
Q2 2021 Aug 16, 2021	BUY	$7.84 - $12.6 $3.81 Million - $6.12 Million	485,949 Added 21.26%	2,771,750 $24.6 Million
Q1 2021 May 17, 2021	BUY	$10.54 - $19.3 $10.1 Million - $18.5 Million	956,964 Added 72.02%	2,285,801 $29 Million
Q4 2020 Feb 16, 2021	BUY	$12.79 - $17.1 $375,642 - $502,227	29,370 Added 2.26%	1,328,837 $18.5 Million
Q3 2020 Nov 10, 2020	BUY	$12.99 - $19.41 $1.71 Million - $2.56 Million	131,701 Added 11.28%	1,299,467 $16.9 Million
Q2 2020 Aug 14, 2020	BUY	$12.19 - $22.96 $5.74 Million - $10.8 Million	471,027 Added 67.6%	1,167,766 $20.4 Million
Q1 2020 May 11, 2020	BUY	$10.08 - $27.21 $7.02 Million - $19 Million	696,739 New	696,739 $10.8 Million

559K

Ticker AVRO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,773,900
Description
AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene that is defective in the...

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

Stay updated on State Street Corp with notifications on news.